皇家华人

header-logo
Main Campus Entrance-MKE
Neurosurgery

Kroner-Milsch Lab

Dr. Antje Kroner-Milsch

The overarching goal of my laboratory is to improve the quality of life and health of persons living with spinal cord injury (SCI). To achieve this goal, our work focuses on targeted control of the secondary tissue damage. Primary tissue damage, most often caused by a mechanical impact, is significantly worsened by multiple secondary processes, which include inflammation and hemorrhage. Current research in my lab is focused on tissue protection after SCI by interrupting hemorrhage induced and inflammatory processes which directly promote tissue damage and neuronal death and result in impaired functional outcome.

One research focus of my lab is the targeted inhibition of pro-inflammatory factors. This approach aims to specifically inhibit harmful, prolonged, and exacerbated inflammation, while maintaining the essential and tissue protective inflammatory processes. Previous experiments have shown the importance of pro-inflammatory factors in mediating inflammatory damage but also directly affecting neuronal survival and function, resulting in impaired recovery. A comprehensive understanding of inflammatory processes after SCI is essential for translational approaches in specifically targeting and inhibiting harmful mediators.

A second focus of my research investigates the role of hemorrhage after SCI. The reactivity of free hemoglobin and its downstream products induces a pronounced inflammatory and tissue toxic response. Interrupting this process will have a significant impact on the tissue preservation and functional outcome.

Ongoing Studies

all
Role of the Pro-inflammatory Cytokines IL-12 and IL-23 in Secondary Damage after Spinal Cord Injury
Funding: Department of Veterans Affairs, VA-ORD
The Functional Role and Therapeutic Potential of Heme Binding Proteins after Cervical SCI
Funding: Wings for Life

Recent Publications

  • (Ryan F, Blex C, Ngo TD, Kopp MA, Michalke B, Venkataramani V, Curran L, Schwab JM, Ruprecht K, Otto C, Jhelum P, Kroner A, David S.) Acta Neuropathol. 2024 Jun 22;147(1):106 PMID: 38907771 PMCID: PMC11193702 06/22/2024

  • (St-Pierre MK, González Ibáñez F, Kroner A, Tremblay MÈ.) J Neuroinflammation. 2023 Nov 21;20(1):273 PMID: 37990235 PMCID: PMC10664529 11/22/2023

  • (David S, Ryan F, Jhelum P, Kroner A.) Neuroscientist. 2023 Oct;29(5):591-615 PMID: 35678019 06/10/2022

  • (Page JJ, Almanza JR, Xiong S, Aishwarya V, Kroner A.) J Neuroimmunol. 2023 Jun 15;379:578103 PMID: 37172370 05/12/2023

  • (Rosas Almanza J, Stehlik KE, Page JJ, Xiong SH, Tabor EG, Aperi B, Patel K, Kodali R, Kurpad S, Budde MD, Tarima S, Swartz K, Kroner A.) J Neurosci Res. 2022 Dec;100(12):2213-2231 PMID: 36089917 SCOPUS ID: 2-s2.0-85137752150 09/13/2022

  • (David S, Jhelum P, Ryan F, Jeong SY, Kroner A.) Antioxid Redox Signal. 2022 Jul;37(1-3):150-170 PMID: 34569265 09/28/2021

  • (Pelisch N, Almanza JR, Stehlik KE, Aperi BV, Kroner A.) J Neuroinflammation. 2021 Apr 03;18(1):87 PMID: 33812368 PMCID: PMC8019158 04/05/2021

  • (Pelisch N, Rosas Almanza J, Stehlik KE, Aperi BV, Kroner A.) eNeuro. 2021;8(2) PMID: 33632814 PMCID: PMC7986543 02/27/2021

  • (Pelisch N, Rosas Almanza J, Stehlik KE, Aperi BV, Kroner A.) J Neuroinflammation. 2020 Nov 27;17(1):362 PMID: 33246483 PMCID: PMC7694914 11/29/2020

  • (Reinhardt DR, Stehlik KE, Satkunendrarajah K, Kroner A.) Exp Neurol. 2020 Sep;331:113381 PMID: 32561411 SCOPUS ID: 2-s2.0-85086575731 06/21/2020

  • (Kroner A, Rosas Almanza J.) Neurosci Lett. 2019 Sep 14;709:134370 PMID: 31283964 07/10/2019

  • (David S, Kroner A, Greenhalgh AD, Zarruk JG, López-Vales R.) J Neuroimmunol. 2018 Aug 15;321:97-108 PMID: 29957394 06/30/2018

Publications of from the

© 2024 皇家华人.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The 皇家华人 (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.